A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS
Starting soon · Phase 1/Phase 2
Conditions studied: Amyotrophic Lateral Sclerosis (ALS)
In brief
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy of SNUG01 in in adult subjects with Amyotrophic Lateral Sclerosis (ALS).
Key facts
- Study ID
- NCT07169175
- Run by
- SineuGene Therapeutics Co., Ltd.
- People needed
- 21
- Starts
- 2025-12-01
- Expected to finish
- 2028-09-30
- Last updated by the study team
- 2025-09-11
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Peking University Third Hospital — Beijing, Beijing Municipality, China
- Fujian Medical University Union Hospital — Fuzhou, Fujian, China
- Second Affiliated Hospital Zhejiang University School of Medicine — Hangzhou, Zhejiang, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.